Sept 18 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics Biotech Inc - announces successful end-of-Phase 2 meeting with FDA for reolysin in metastatic breast cancer
* Oncolytics Biotech Inc - FDA provided guidance that if study achieves its primary endpoint, then it will be only study required for BLA approval